Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene (This gene does not contain this module)
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: RPS6

Summary for RPS6

Gene information	Gene symbol	RPS6
	Ensembl ID	ENSG00000137154
	Entrez ID	6194
	Gene name	ribosomal protein S6
	Synonyms	S6
	Gene type	protein_coding
	UniProtAcc	P62753

Top

Dataset with differentially expressed gene: RPS6

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.530865	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.269752	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.441192	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.362905	1.46e-13
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.319459	1.77e-02
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.286011	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.317937	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.299466	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.401011	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.289061	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.255724	5.53e-10
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.255687	1.54e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.982616	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.339613	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.312078	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.31736	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.267225	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.60831	1.35e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.357963	4.20e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.379899	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	0.32616	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	0.429751	4.83e-03
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	0.633912	4.07e-03
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-1.16561	5.29e-32
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.402335	6.40e-06
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.313097	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	-0.577088	3.12e-04
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.710743	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.408897	1.25e-05
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.315286	2.64e-12
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.435418	1.88e-38
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.272549	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	0.301198	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.351064	3.54e-16
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.735674	1.40e-11
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-1.07737	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.313435	2.52e-14
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.560108	4.66e-30
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.463954	3.86e-18
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.653651	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.868148	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.403376	8.00e-37
GSE158457	PDX cells	Cell line	Acute lymphoblastic leukemia	T-cell acute lymphoblastic leukemia (ALL)	Targeted therapy	dasatinib	NA	Malignant cells	-0.286318	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.350523	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	0.430369	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	0.509363	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.466787	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.459329	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.59198	4.40e-08
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.345491	5.05e-16
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD4+ T cells	0.474567	4.16e-08
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	1.31616	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.626551	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.98075	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-1.1219	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.868028	0.00e+00

Top

Expression of RPS6 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to RPS6

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
RPS6	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating RPS6

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating RPS6

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
RPS6	metacluster_191.2	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).
RPS6	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
RPS6	metacluster_166.4	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).
RPS6	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
RPS6	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
RPS6	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
RPS6	hdpi__ETV4	ETV4 (directAnnotation).
RPS6	taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP	ETV5; FOXI1 (directAnnotation).
RPS6	cisbp__M02645	ETS1 (directAnnotation).
RPS6	taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGTMATTA_CAP_repr	ETV2; HOXA2 (directAnnotation).
RPS6	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
RPS6	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
RPS6	metacluster_166.2	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).
RPS6	taipale_tf_pairs__HOXB2_ELK3_RSCGGAAGTMRTTA_CAP	ELK3; HOXB2 (directAnnotation).
RPS6	jaspar__MA1483.2	ELF2 (directAnnotation).
RPS6	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
RPS6	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
RPS6	taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT	ELK1; HOXA1 (directAnnotation).
RPS6	taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP	ELF1; HOXB2 (directAnnotation).
RPS6	cisbp__M08198	ELF1 (directAnnotation).
RPS6	taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr	ERF; FOXI1 (directAnnotation).
RPS6	hdpi__TP73	TP73 (directAnnotation).
RPS6	taipale_tf_pairs__ERF_HES7_NCCGGAANNNNNNCACGYGNN_CAP_repr	ERF; HES7 (directAnnotation).
RPS6	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	ELK1; FOXI1 (directAnnotation).
RPS6	hdpi__FLI1	FLI1 (directAnnotation).
RPS6	metacluster_138.2	ELF1; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK3; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ERF; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS2; ETS2; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV5; ETV5; FEV; FLI1; FLI1; GABPA; GABPA; KMT2B; SPDEF; SPDEF; SPDEF; ZBTB11; ZNF518A; ZNF580 (directAnnotation). ELF1; ELF2; ELF4; ELK1; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV1; ETV2; ETV3; ETV4; ETV5; FEV; FLI1; FLI1; GABPA; SPDEF; SPDEF (inferredBy_Orthology).
RPS6	jaspar__MA1957.1	ELK1 (directAnnotation).
RPS6	hocomoco__OTX1_HUMAN.H11MO.0.D	OTX1 (directAnnotation).
RPS6	transfac_pro__M05522	ZNF341 (directAnnotation).
RPS6	taipale_tf_pairs__FOXO1_ETV4_RCCGGAWGTKKN_CAP	ETV4; FOXO1 (directAnnotation).
RPS6	taipale_tf_pairs__ERF_HOXA3_RSCGGAWNNNNNNNYMATTA_CAP_repr	ERF; HOXA3 (directAnnotation).
RPS6	taipale_tf_pairs__TEAD4_SPIB_RGAATGCGGAAGTN_CAP_1	SPIB; TEAD4 (directAnnotation).
RPS6	taipale_tf_pairs__ETV2_FOXO6_RCCGGATGTTKWN_CAP	ETV2; FOXO6 (directAnnotation).
RPS6	taipale_tf_pairs__ETV2_SOX15_RSCGGAANNNNNNNYWTTGT_CAP_repr	ETV2; SOX15 (directAnnotation).
RPS6	transfac_pro__M06660	ZNF670 (directAnnotation).
RPS6	taipale_tf_pairs__ELK1_PAX5_RSCGGAACYACGCWYSANTG_CAP_repr	ELK1; PAX5 (directAnnotation).
RPS6	metacluster_167.7	IRF8 (inferredBy_Orthology).
RPS6	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	ETV4; GCM1 (directAnnotation).
RPS6	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	ETV4; TEAD4 (directAnnotation).
RPS6	transfac_pro__M06554	ZNF483 (directAnnotation).
RPS6	jaspar__MA1708.1	ETV7 (directAnnotation).
RPS6	stark__RCGCMATTW	YY1 (inferredBy_Orthology).
RPS6	transfac_pro__M07392	PITX3 (directAnnotation).
RPS6	jaspar__MA1937.1	HOXB13 (directAnnotation).
RPS6	taipale_tf_pairs__HOXD12_TBX21_AGGTGTKAAGTCGTAAA_CAP_repr	HOXD12; TBX21 (directAnnotation).
RPS6	transfac_pro__M04826	EP300 (directAnnotation).
RPS6	jaspar__MA1933.1	SREBF2 (directAnnotation).
RPS6	taipale_tf_pairs__ETV5_EVX1_RSCGGWAATKR_CAP	ETV5; EVX1 (directAnnotation).
RPS6	taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP	ELK1; FOXO1 (directAnnotation).
RPS6	taipale_tf_pairs__ETV2_FOXI1_RSCGGATGTTKW_CAP	ETV2; FOXI1 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
RPS6	"Artenimol"	DB11638	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."